LifeSiteNews has been permanently banned on YouTube. Click HERE to sign up to receive emails when we add to our video library.
April 27, 2021 (Children’s Health Defense) – More than four months into the rollout of the Pfizer-BioNTech and Moderna vaccines in the U.S., health officials launched a clinical trial to study allergic reactions to the vaccines.
The National Institute of Allergy and Infectious Diseases (NIAID) announced the trial April 7, one day after researchers in the UK published a study confirming polyethylene glycol (PEG), a compound in the two vaccines, caused the anaphylactic reaction experienced by a woman who received the Pfizer vaccine.
However, a close look at the NIAID trial guidelines reveals the study excludes individuals most likely to experience allergic reactions to the vaccines — those with PEG allergies and autoimmune disorders.
UK study focused on 52-year-old woman
On April 6, researchers from the Department of Allergy and Oncology at Cambridge University Hospitals and the National Health Service Foundation Trust in Cambridge, UK, published a research letter in Clinical and Experimental Allergy. The letter — “Polyethylene Glycol (PEG) Is a Cause of Anaphylaxis to the Pfizer/BioNTech mRNA COVID-19 Vaccine” — confirmed PEG as the culprit in the increasing number of reports of anaphylaxis following administration of the Pfizer and Moderna mRNA vaccines.
The remainder of this article is available in its entirety at LifeSite News
The views expressed in this news alert by the author do not directly represent that of The Christian Journal or its editors
